Retinoic acid pathway activity in wilms tumors and characterization of biological responses in vitro

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Wegert, Jenny ^a   Bausenwein, Sabrina ^a   Kneitz, Susanne ^a   Roth, Sabine ^a   Graf, Norbert ^b   Geissinger, Eva ^a   Gessler, Manfred ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Nephroblastoma; Primary tumor cell culture; Retinoic acid; Tumor model; Wilms tumor

Indexed keywords

ALITRETINOIN; FENRETINIDE; RETINOIC ACID; VORINOSTAT; ANTINEOPLASTIC AGENT; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

ADVANCED CANCER; APOPTOSIS; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG EFFICACY; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MESOBLASTIC NEPHROMA; MUSCLE DEVELOPMENT; NEPHROBLASTOMA; NERVE CELL DIFFERENTIATION; SIGNAL TRANSDUCTION; TUMOR CELL; GENE EXPRESSION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; GENE EXPRESSION; HUMANS; NUCLEAR PROTEINS; ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRETINOIN; TUMOR CELLS, CULTURED; WILMS TUMOR;

EID: 80455126026     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-136     Document Type: Article

References (26)

1. Ruteshouser EC, Robinson SM, Huff V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 2008, 47:461-470. 10.1002/gcc.20553, 18311776.
2. Sonn G, Shortliffe LM. Management of Wilms tumor: current standard of care. Nat Clin Pract Urol 2008, 5:551-560. 10.1038/ncpuro1218, 18836464.
3. Pastore G, Znaor A, Spreafico F, Graf N, Pritchard-Jones K, Steliarova-Foucher E. Malignant renal tumours incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006, 42:2103-2114. 10.1016/j.ejca.2006.05.010, 16919774.
4. Zirn B, Hartmann O, Samans B, Krause M, Wittmann S, Mertens F, Graf N, Eilers M, Gessler M. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters. Int J Cancer 2006, 118:1954-1962. 10.1002/ijc.21564, 16287080.
5. Zirn B, Samans B, Spangenberg C, Graf N, Eilers M, Gessler M. All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene 2005, 24:5246-5251. 10.1038/sj.onc.1208725, 15897880.
6. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003, 197:185-192. 10.1016/S0304-3835(03)00108-3, 12880980.
7. Armstrong JL, Redfern CP, Veal GJ. 13-cis retinoic acid and isomerisation in paediatric oncology--is changing shape the key to success?. Biochem Pharmacol 2005, 69:1299-1306. 10.1016/j.bcp.2005.02.003, 15826600.
8. Wu JM, DiPietrantonio AM, Hsieh TC. Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis 2001, 6:377-388. 10.1023/A:1011342220621, 11483862.
9. Epping MT, Wang L, Plumb JA, Lieb M, Gronemeyer H, Brown R, Bernards R. A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci USA 2007, 104:17777-17782. 10.1073/pnas.0702518104, 2077016, 17968018.
10. Hahn CK, Ross KN, Warrington IM, Mazitschek R, Kanegai CM, Wright RD, Kung AL, Golub TR, Stegmaier K. Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci USA 2008, 105:9751-9756. 10.1073/pnas.0710413105, 2474517, 18607002.
11. Witt O, Hammerling S, Stockklausner C, Schenk JP, Gunther P, Behnisch W, Hamad B, Al Mulla NA, Kulozik A. 13-cis retinoic acid treatment of a patient with chemotherapy refractory nephroblastomatosis. J Pediatr Hematol Oncol 2009, 31:296-299. 10.1097/MPH.0b013e3181979c70, 19346886.
12. Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 2006, 24:3423-3430. 10.1200/JCO.2005.03.9271, 16849757.
13. Shamberger RC, Anderson JR, Breslow NE, Perlman EJ, Beckwith JB, Ritchey ML, Haase GM, Donaldson M, Grundy PE, Weetman R, et al. Long-term outcomes for infants with very low risk Wilms tumor treated with surgery alone in National Wilms Tumor Study-5. Ann Surg 2010, 251:555-558. 10.1097/SLA.0b013e3181c0e5d7, 2836016, 20142733.
14. Wegert J, Bausenwein S, Roth S, Graf N, Geissinger E, Gessler M. Characterization of Primary Wilms Tumor Cultures as an In Vitro Model. Genes Chromosomes Cancer 2011,
15. Li W, Kessler P, Williams BR. Transcript profiling of Wilms tumors reveals connections to kidney morphogenesis and expression patterns associated with anaplasia. Oncogene 2005, 24:457-468. 10.1038/sj.onc.1208228, 15531917.
16. Gupta A, Kessler P, Rawwas J, Williams BR. Regulation of CRABP-II expression by MycN in Wilms tumor. Exp Cell Res 2008, 314:3663-3668. 10.1016/j.yexcr.2008.09.029, 18955045.
17. Liebler S, Uberschar B, Kubert H, Brems S, Schnitger A, Tsukada M, Zouboulis CC, Ritz E, Wagner J. The renal retinoid system: time-dependent activation in experimental glomerulonephritis. Am J Physiol Renal Physiol 2004, 286:F458-465. 10.1152/ajprenal.00173.2003, 14583434.
18. Barlow JW, Wiley JC, Mous M, Narendran A, Gee MF, Goldberg M, Sexsmith E, Malkin D. Differentiation of rhabdomyosarcoma cell lines using retinoic acid. Pediatr Blood Cancer 2006, 47:773-784. 10.1002/pbc.20650, 16283617.
19. Reynolds CP, Kane DJ, Einhorn PA, Matthay KK, Crouse VL, Wilbur JR, Shurin SB, Seeger RC. Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res 1991, 366:203-211.
20. Ponzoni M, Bocca P, Chiesa V, Decensi A, Pistoia V, Raffaghello L, Rozzo C, Montaldo PG. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res 1995, 55:853-861.
21. Hail N, Kim HJ, Lotan R. Mechanisms of fenretinide-induced apoptosis. Apoptosis 2006, 11:1677-1694. 10.1007/s10495-006-9289-3, 16850162.
22. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998, 391:811-814. 10.1038/35895, 9486654.
23. Wittmann S, Zirn B, Alkassar M, Ambros P, Graf N, Gessler M. Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis. Genes Chromosomes Cancer 2007, 46:163-170. 10.1002/gcc.20397, 17099873.
24. Wittmann S, Wunder C, Zirn B, Furtwangler R, Wegert J, Graf N, Gessler M. New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors. Genes Chromosomes Cancer 2008, 47:386-395. 10.1002/gcc.20544, 18260125.
25. Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002, 18(Suppl 1):S96-104. 10.1093/bioinformatics/18.suppl_1.S96, 12169536.
26. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.